Maravai Surges with Strong Q2 2026 Results | Business and Finance News

Maravai LifeSciences delivered a powerhouse Q2 2026 earnings report with revenue soaring 9% to $51.4M, fueled by a 12% surge in TriLink and 3% growth in Cygnus—its fifth straight quarter of expansion. Profitability took a leap, with adjusted gross margin jumping over 1,600 basis points. The company also slashed debt by half through a June refinancing, cutting borrowings to $150M with maturities pushed to 2032. Strategic wins include rapid adoption of their ModTail tech (125+ customers in a year), new GMP enzyme launches, and expanded Cygnus offerings—all backed by a growing IP portfolio. They’re staying on track for full-year 2026 revenue of $205M–$215M and raising EBITDA guidance to $33M–$35M, fueled by cost discipline and product mix improvements. With stronger margins, leaner debt, and accelerating commercial momentum, Maravai is positioning itself for sustained, high-growth success as customer programs move from lab to market. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/e5f3ccb284b1500f